
LeMaitre Vascular (LMAT) Stock Forecast & Price Target
LeMaitre Vascular (LMAT) Analyst Ratings
Bulls say
LeMaitre Vascular is expected to continue its strong financial performance, with FY/26 revenue growth projected at 12%. Price increases, favorable product mix, and international expansion are expected to drive growth. The increase in dividend and continued focus on profitability and cash flow also contribute to a positive outlook on the company. The current cash balance of $359.1 million and potential for future M&A activities provide further potential for growth.
Bears say
LeMaitre Vascular is facing several challenges that will affect its financial performance, including slower international adoption of its products and potential regulatory delays. The company's heavy reliance on a single product, the mRidium pump, also poses a significant risk to its financial stability. Despite its positive growth in the past, the company's stock may face downward pressure if it cannot effectively diversify its product portfolio and reduce its product concentration risk. Overall, the company's financial outlook for FY/26 may be impacted by these challenges, and it may struggle to meet its revenue and earnings targets.
This aggregate rating is based on analysts' research of LeMaitre Vascular and is not a guaranteed prediction by Public.com or investment advice.
LeMaitre Vascular (LMAT) Analyst Forecast & Price Prediction
Start investing in LeMaitre Vascular (LMAT)
Order type
Buy in
Order amount
Est. shares
0 shares